What's Slowing Speed to Market in Life Sciences

Considering the increasingly high costs of bringing drugs and medical devices to market—in contrast to their dwindling approval ratings—life sciences organizations must squeeze the most value out of their data. Due to the market advantage of strong brand recognition and product loyalty, expediting speedto-market continues to be a top priority. A conversation with Matt Ferrari, Chief Technology Officer and Co-Founder at ClearDATA, reveals the challenges that are slowing down life sciences organizations’ product pipelines and the solutions available to overcome them.